We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Innovative Technology Minimizes Need for Invasive Mechanical Ventilation

By HospiMedica International staff writers
Posted on 01 Mar 2022
Print article
Image: Frost & Sullivan applauds Inspira’s ART System (Photo courtesy of Inspira Technologies)
Image: Frost & Sullivan applauds Inspira’s ART System (Photo courtesy of Inspira Technologies)

An early extracorporeal respiratory support system that elevates oxygen saturation levels is designed to be a new standard of care as a second-line treatment to minimize the need for invasive mechanical ventilation (MV).

Inspira Technologies’ (Ra'anana, Israel) ART system has been awarded the 2021 Europe Technology Innovation Leadership Award by Frost & Sullivan based on findings from its analysis of the European artificial respiratory market. Inspira is developing the ART system, a cost effective early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory patients. The ART is designed to utilize a hemo-protective flow approach aimed at rebalancing oxygen saturation levels while patients are awake and breathing, potentially minimizing the patient's need for mechanical ventilation.

A variety of ART system features set it apart from ECMO. ECMO treatment requires two large cannulas (21-25 French) single lumen cannulas used to withdraw and return 5 to 7 liters of blood per minute. In comparison, the ART treatment is designed to use one dual-lumen cannula (16 to 21 French) for withdrawing and returning 1 to 1.5 liters of blood per minute. Moreover, ECMO is a high-flow device that cannot support low-flow treatment; the ART system optimizes the effectiveness profile of the low-flow extracorporeal treatment. The ART includes a proprietary disposable support cartridge with an oxygenator, tubes, and pump-head. The cartridge is a fully sterilized, closed system that incorporates an innovative auto-priming system that prevents air embolisms and minimizes the need for perfusionists who are necessary for ECMO operation.

Patients are medically induced into a coma during ECMO treatment, whereas the ART system aims to treat patients while they are awake and spontaneously breathing. There is no need for induced medical comas with the ART system, allowing patients to breathe spontaneously and communicate with their surroundings, thus reducing the risks and complications associated with MV. The company expects submission of the Class II 510(k) for its' Extracorporeal Life Support system (ECLS) in H1-2023, followed by initial market penetration in the respiratory care industry. Furthermore, the company plans to file its novel treatment, the ART system, for de-novo or PMA to the US Food and Drug Administration (FDA) in H2-2023.

"Inspira Technologies' ART system differs significantly from extracorporeal membrane oxygenation (ECMO) in many areas, including its intent of use, patient population, system size, and potential risks for the patient," noted Debarati Sengupta, Industrial Analyst at Frost & Sullivan. "Unlike standard ECMO treatment, the ART system allows for early intervention. Alternative treatments, such as invasive mechanical ventilation, can be applied alongside the ART system if a patient's health continues to deteriorate. The ART system demonstrates the company's excellence in innovation within the respiratory care industry."

"Inspira will potentially overcome the complicated setup associated with ECMO and other systems, resulting in an efficient and effective procedure that safeguards a patient's health," added Samantha Fisher, Best Practices Research Analyst for Frost & Sullivan. "The innovation of the ART system is that it overcomes the limitations of its predecessors to deliver a less-invasive respiratory support system."

Related Links:
Inspira Technologies

Print article


Surgical Techniques

view channel
Image: A minimally invasive diagnostic biomarker strategy has proven successful in detecting early esophageal cancer (Photo courtesy of Pexels)

Minimally Invasive Device Combined With Molecular Biomarkers Detects Early Esophageal Cancer

Esophageal cancer remains the sixth-most common cause of cancer death worldwide, claiming the lives of more than half a million people annually. Esophageal squamous cell carcinoma (ESCC) comprises 80%... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.